Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Aldoss, Ibrahim; C. Issa, Ghayas; J. Thirman, Michael; F. DiPersio, John; Arellano, Martha; S. Blachly, James; N. Mannis, Gabriel; E. Perl, Alexander; S. Dickens, David; M. McMahon, Christine; Traer, Elie; Michel Zwaan, C.; Grove, Carolyn; M. Stone, Richard; J. Shami, Paul; Mantzaris, Ioannis; Greenwood, Matthew; Shukla, Neerav; Cuglievan, Branko; Gu, Yu; G. Bagley, Rebecca; Madigan, Kate; Sunkaraneni, Soujanya; Van Nguyen, Huy; McNeer, Nicole; M. Stein, Eytan

doi:10.1182/blood-2023-192042

Public

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Published in Blood • Nov 21, 2023

Authors:

Ibrahim Aldoss

Ghayas C. Issa

Michael J. Thirman

Abstract

Background: Most patients (pts) with histone-lysine N-methyltransferase 2A (KMT2A)-rearranged (KMT2Ar) acute leukemia, relapse after conventional chemotherapy and hematopoietic stem cell transplant (HSCT). Remission rates after relapse (complete remission [CR], 5%) and median overall survival (2.4 m...

Subject

Medicine

Acute leukemia

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!